60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
公司代碼SXTP
公司名稱60 Degrees Pharmaceuticals Inc
上市日期Jul 12, 2023
CEODow (Geoffrey S)
員工數量3
證券類型Ordinary Share
年結日Jul 12
公司地址1025 Connecticut Avenue Nw
城市WASHINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20036
電話12023275422
網址https://60degreespharma.com/
公司代碼SXTP
上市日期Jul 12, 2023
CEODow (Geoffrey S)